11β-hydroxylase deficiency physical examination: Difference between revisions

Jump to navigation Jump to search
Line 1: Line 1:
__NOTOC__
__NOTOC__
{{Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency}}
{{11β-hydroxylase deficiency}}
 
{{CMG}}; {{AE}} {{MJ}}
{{CMG}}; {{AE}} {{MJ}}
==Overview==
==Overview==
Line 25: Line 26:




[[File:JCRPE-4-213-g1.jpg|thumb|none|350 px|Genital ambiguity]]
[[File:JCRPE-4-213-g1.jpg|thumb|none|350 px|[[Ambiguous genitalia|Ambiguous genitalia]]


* Male:
* Male:

Revision as of 15:55, 3 August 2017

Congenital adrenal hyperplasia main page

11β-hydroxylase deficiency Microchapters

Home

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating 11β-hydroxylase deficiency from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

11β-hydroxylase deficiency physical examination On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of 11β-hydroxylase deficiency physical examination

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on 11β-hydroxylase deficiency physical examination

CDC on 11β-hydroxylase deficiency physical examination

11β-hydroxylase deficiency physical examination in the news

Blogs on 11β-hydroxylase deficiency physical examination

Directions to Hospitals Treating Congenital adrenal hyperplasia due to 11β-hydroxylase deficiency

Risk calculators and risk factors for 11β-hydroxylase deficiency physical examination

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mehrian Jafarizade, M.D [2]

Overview

Patients with 11β-hydroxylase deficiency usually appear healthy. Physical examination of patients with 11β-hydroxylase deficiency is usually remarkable for gynecomastia, hyperpigmentation, hypertension, and ambiguous genitalia.

Physical Examination

Appearance of the Patient

Vital Signs

Head

Skin

Genitals


[[File:JCRPE-4-213-g1.jpg|thumb|none|350 px|Ambiguous genitalia

References

  1. El-Maouche D, Arlt W, Merke DP (2017). "Congenital adrenal hyperplasia". Lancet. doi:10.1016/S0140-6736(17)31431-9. PMID 28576284.
  2. Zachmann M, Tassinari D, Prader A (1983). "Clinical and biochemical variability of congenital adrenal hyperplasia due to 11 beta-hydroxylase deficiency. A study of 25 patients". J. Clin. Endocrinol. Metab. 56 (2): 222–9. doi:10.1210/jcem-56-2-222. PMID 6296182.
  3. Zadik Z, Kahana L, Kaufman H, Benderli A, Hochberg Z (1984). "Salt loss in hypertensive form of congenital adrenal hyperplasia (11-beta-hydroxylase deficiency)". J. Clin. Endocrinol. Metab. 58 (2): 384–7. doi:10.1210/jcem-58-2-384. PMID 6607265.